Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2006-11-19
pubmed:abstractText
Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) and granulocyte colony-stimulating factor (G-CSF) promote haematopoietic progenitor cell maturation. We reviewed the findings for healthy volunteers/donors who developed haematological malignancies following PEG-rHuMGDF or G-CSF administration. Information was reviewed for three of 538 volunteers who received PEG-rHuMGDF in clinical trials and two of 200 donors who underwent G-CSF mobilised stem cell harvesting procedures for sibling stem cell transplants. Mantle cell, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia were diagnosed 1-5 years after PEG-rHuMGDF exposure among three volunteers. For one patient, thrombocytopenia due to autoantibodies to PEG-rHuMGDF developed shortly after PEG-rHuMGDF administration and persisted until chemotherapy was administered. All three achieved complete remission, although one patient relapsed. Acute myeloid leukaemia was diagnosed 4 and 5 years after G-CSF mobilisation in two donors who underwent peripheral blood stem cell donation for sibling allogeneic haematopoietic stem cell transplantation. Following intensive chemotherapy, one died from acute leukaemia and the second is in complete remission. Controversy exists over the appropriateness of administering haematopoietic growth factors to healthy individuals. While a causal relationship with haematological malignancies cannot be demonstrated, long-term follow-up among healthy individuals who receive haematopoietic growth factors is needed.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0007-1048
pubmed:author
pubmed:issnType
Print
pubmed:volume
135
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
642-50
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:17054431-Adult, pubmed-meshheading:17054431-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17054431-Autoantibodies, pubmed-meshheading:17054431-Clinical Trials as Topic, pubmed-meshheading:17054431-Female, pubmed-meshheading:17054431-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:17054431-Hematologic Neoplasms, pubmed-meshheading:17054431-Hematopoietic Cell Growth Factors, pubmed-meshheading:17054431-Humans, pubmed-meshheading:17054431-Leukemia, Erythroblastic, Acute, pubmed-meshheading:17054431-Leukemia, Lymphocytic, Chronic, B-Cell, pubmed-meshheading:17054431-Leukemia, Monocytic, Acute, pubmed-meshheading:17054431-Lymphoma, B-Cell, pubmed-meshheading:17054431-Lymphoma, Mantle-Cell, pubmed-meshheading:17054431-Male, pubmed-meshheading:17054431-Middle Aged, pubmed-meshheading:17054431-Peripheral Blood Stem Cell Transplantation, pubmed-meshheading:17054431-Polyethylene Glycols, pubmed-meshheading:17054431-Recombinant Proteins, pubmed-meshheading:17054431-Thrombopoietin, pubmed-meshheading:17054431-Tissue Donors
pubmed:year
2006
pubmed:articleTitle
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
pubmed:affiliation
VA Midwest Center for Health Services and Policy Research, the Jesse Brown VA Medical Center, Chicago, IL, USA. cbenne@northwestern.edu
pubmed:publicationType
Journal Article, Case Reports, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural